

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies

Maria-Victoria Mateos,¹ Andrew Spencer,² Ajay K. Nooka,³ Ludek Pour,⁴ Katja Weisel,⁵ Michele Cavo,⁶ Jacob P. Laubach,⁷ Gordon Cook,⁸ Shinsuke Iida,⁹ Lotfi Benboubker,¹⁰ Saad Z. Usmani,¹¹ Sung-Soo Yoon,¹² Nizar J. Bahlis,¹³ Christopher Chiu,¹⁴ Jon Ukropec,¹⁵ Jordan M. Schecter,¹⁶ Xiang Qin,¹⁴ Lisa O'Rourke,¹⁴ and Meletios A. Dimopoulos¹⁷

¹University Hospital of Salamanca/IBSAL, Salamanca, Spain; ²Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia; ³Winship Cancer Institute, Emory University, Atlanta, GA, USA; ⁴University Hospital Brno, Brno, Czech Republic; ⁵University Medical Center of Hamburg-Eppendorf, Hamburg, Germany; ⁶Institute of Hematology Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy; ⁷Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; ⁸St James's Institute of Oncology, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, United Kingdom; ⁹Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; ¹⁰Service d'Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire (CHRU), Tours, France; ¹¹Levine Cancer Institute/Atrium Health, Charlotte, NC, USA; ¹²Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea; ¹³Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada; ¹⁴Janssen Research and Development, LLC, Spring House, PA, USA; ¹⁵Janssen Global Medical Affairs, Horsham, PA, USA; ¹⁶Janssen Research & Development, LLC, Raritan, NJ, USA and ¹⁷National and Kapodistrian University of Athens, Athens, Greece

©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2019.217448

Received: January 23, 2019.

Accepted: June 20, 2019.

Pre-published: June 20, 2019.

Correspondence: MARIA-VICTORIA MATEOS - mvmateos@usal.es

Supplemental Appendix.

Supplemental Table 1. MRD-negative status (10^{-5} sensitivity threshold) according to an age-based analysis in POLLUX and CASTOR among patients who received 1 prior line of therapy.

	POLLUX								
	ITT			65-74 years			≥75 years		
	D-Rd (n=149)	Rd (n=146)	P value	D-Rd (n=62)	Rd (n=59)	P value	D-Rd (n=17)	Rd (n=16)	P value
MRD, n (%)									
Sensitivity threshold, 10^{-5}	38 (25.5)	12 (8.2)	0.000053	15 (24.2)	5 (8.5)	0.017519	4 (23.5)	2 (12.5)	0.407414

	CASTOR								
	ITT			65-74 years			≥75 years		
	D-Vd (n=122)	Vd (n=113)	P value	D-Vd (n=47)	Vd (n=38)	P value	D-Vd (n=8)	Vd (n=17)	P value
MRD, n (%)									
Sensitivity threshold, 10^{-5}	17 (13.9)	3 (2.7)	0.001138	9 (19.1)	1 (2.6)	0.011285	1 (12.5)	0	0.123775

MRD, minimal residual disease; ITT, intent-to-treat; D-Rd, daratumumab/lenalidomide/dexamethasone; Rd, lenalidomide/dexamethasone; D-Vd, daratumumab/bortezomib/dexamethasone; Vd, bortezomib/dexamethasone.

Supplemental Table 2. MRD-negative status (10^{-4} and 10^{-6} sensitivity thresholds) according to an age-based analysis of patients in POLLUX and CASTOR.

MRD, n (%)	POLLUX ^a								
	ITT			65-74 years			≥75 years		
	D-Rd (n=286)	Rd (n=283)	<i>P</i> value	D-Rd (n=124)	Rd (n=108)	<i>P</i> value	D-Rd (n=29)	Rd (n=35)	<i>P</i> value
Sensitivity threshold									
10^{-4}	97 (33.9)	28 (9.9)	<0.000001	37 (29.8)	13 (12.0)	0.000793	11 (37.9)	2 (5.7)	0.001029
10^{-6}	37 (12.9)	8 (2.8)	0.000003	17 (13.7)	3 (2.8)	0.001811	1 (3.4)	2 (5.7)	0.665621
MRD, n (%)	CASTOR ^a								
	ITT			65-74 years			≥75 years		
	D-Vd (n=251)	Vd (n=247)	<i>P</i> value	D-Vd (n=96)	Vd (n=87)	<i>P</i> value	D-Vd (n=23)	Vd (n=35)	<i>P</i> value
Sensitivity threshold									
10^{-4}	47 (18.7)	9 (3.6)	<0.000001	25 (26.0)	3 (3.4)	0.000006	3 (13.0)	0	0.016014
10^{-6}	12 (4.8)	2 (0.8)	0.004763	6 (6.3)	1 (1.1)	0.057414	0	0	N/A

MRD, minimal residual disease; ITT, intent-to-treat; D-Rd, daratumumab/lenalidomide/dexamethasone; Rd, lenalidomide/dexamethasone; D-Vd, daratumumab/bortezomib/dexamethasone; Vd, bortezomib/dexamethasone; N/A, not available.

^aBased on the ITT analysis set.